[Mianserin agranulocytosis followed by oxitriptan eosinophilia].
A patient suffering from endogenous depression was treated with mianserin and developed agranulocytosis. After recovering from this, and with the depression in remission, the patient was given L-tryptophan. When this medication was removed from the market, due to the newly described eosinophilia-myalgia syndrome, a change was made to oxitriptan, which then caused a serious asymptomatic eosinophilia. No similar cases have yet been reported. Following withdrawal of oxitriptan, the eosinophilia disappeared. Evidence for any other cause of the condition was not found. Causes and physiopathology of drug-induced agranulocytosis and eosinophilia and the circumstances of such complications following use of mianserin and oxitriptan are discussed.
García
C
C
Psychiatrisches Krankenhaus, Bad Hersfeld.
D006916:5-Hydroxytryptophan / Q000009:adverse effects* / Q000627:therapeutic use; D000380:Agranulocytosis / Q000097:blood / Q000139:chemically induced*; D001772:Blood Cell Count / Q000187:drug effects; D003866:Depressive Disorder / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D004802:Eosinophilia / Q000097:blood / Q000139:chemically induced*; D016603:Eosinophilia-Myalgia Syndrome / Q000097:blood; D006801:Humans; D008297:Male; D008803:Mianserin / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged
D008803:Mianserin; D006916:5-Hydroxytryptophan
Mianserinagranulozytose gefolgt von Oxitriptaneosinophilie.